Pfizer Inc (PFE)

$25.95 +0.16 (0.62%)
Market Cap 146.99B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.39
Forward PE 8.59
Profit Margin 12.42%
Debt to Equity Ratio 0.71
Volume 20,181,537
Avg Vol 37,192,375
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 77%
Beta 0.35
Analysts Sell
Price Target $29.28

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
TornadoChasers
TornadoChasers May. 22 at 9:20 AM
$RVSN $INTC $PFE Medical runners
0 · Reply
framus_morrigan
framus_morrigan May. 22 at 8:19 AM
$PFE it could go very bearish this month but it didn't. So I'm reviewing the weekly chart. Bull channel while $25 keeps holding. Weekly chart
0 · Reply
Roctoc3880
Roctoc3880 May. 22 at 6:13 AM
$PFE buy
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 3:39 AM
$SLS - the 80th Event PR and ensuing Share Price Launch is Imminent. - Phase 3 Registrational Results and FDA Green light worth $40B to big Pharma - are Coming. ANY - DAY - NOW - GPS P3 Results - truly worth $40B + the Instant the REGAL Results are announced - GPS MOS 30-36 months, BAT 8-10 --- T1 Trading Halt - Gap Up into the $10B MCap Range / $50 Per Share - AND CLIMBING —- > And to Bottom LINE 009 - its worth $27 Per Share Right Now / TAMBICICLIB Will Be FDA Approved - the Market Has yet to appreciate its value. -- Gleevic - Imatinib, Imbrutinib -- Imbruvica, -- Upadactinib -- Rinvoq Upadactinib <- say that 3 x fast $PFE Pfizers' Ibrance - Palbociclib CDKinase Inhibitor Novartis' Kisqali -Ribociclib CDKinase Inhibitor $LLY Eli Lilly's Verzenio - Abemaciclib CDKinase Inhibitor $SLS Tambiciclib CDKInase Inhibitor reddit.com/r/sellasLifescience ... for anyone interested in DD/ i been here -invested a long time/ if you have an interest in $
0 · Reply
biolover
biolover May. 22 at 1:11 AM
$LLY $NVO $PFE $VKTX Novo dropped its dual agonist NN130 since then Due to Poor efficacy / telorability , and Bourla decided to run after GLp1 / amylin in phase 1 that will be a failure due to GI issues.
0 · Reply
morgangj
morgangj May. 22 at 1:09 AM
$PFE
0 · Reply
biolover
biolover May. 22 at 1:07 AM
$LLY $PFE $VKTX did Bourla look at numbers below prior to being stingy and running after Metsera ?
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 12:14 AM
$SLS it is inevitable - the 80th Event PR is coming, Phase 3 Registrational Results and FDA Green light worth $40B to big Pharma - are Coming. ANY - DAY - NOW, GPS P3 Results - truly worth $40B + the Instant the REGAL Results are announced - GPS MOS 30-36 months, BAT 8-10 --- T1 Trading Halt - Gap Up into the $10B MCap Range / $50 Per Share - AND CLIMBING And to Bottom LINE 009 - its worth $27 Per Share Right Now / TAMBICICLIB Will Be FDA Approved - the Market Has yet to appreciate its value. -- Gleevic - Imatinib, Imbrutinib -- Imbruvica, -- Upadactinib -- Rinvoq Upadactinib <- say that 3 x fast $PFE Pfizers' Ibrance - Palbociclib CDKinase Inhibitor Novartis' Kisqali -Ribociclib CDKinase Inhibitor $LLY Eli Lilly's Verzenio - Abemaciclib CDKinase Inhibitor $SLS Tambiciclib CDKInase Inhibitor reddit.com/r/sellasLifescience ... for anyone interested in DD/ i been here -invested a long time/ if you have an interest in $
1 · Reply
morgangj
morgangj May. 21 at 10:15 PM
$PFE
1 · Reply
Micheal_Pothead
Micheal_Pothead May. 21 at 7:49 PM
$PFE okay I’m getting worried now
1 · Reply
Latest News on PFE
Moderately bullish activity in Pfizer with shares up 0.41%

2026-05-20T17:00:11.000Z - 1 day ago

Moderately bullish activity in Pfizer with shares up 0.41%

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

May 20, 2026, 9:00 AM EDT - 1 day ago

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

Pfizer announces pneumococcal conjugate vaccine candidate data

2026-05-20T09:30:10.000Z - 2 days ago

Pfizer announces pneumococcal conjugate vaccine candidate data

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

May 20, 2026, 5:08 AM EDT - 2 days ago

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

May 20, 2026, 5:05 AM EDT - 2 days ago

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’

2026-05-18T17:01:06.000Z - 3 days ago

PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’

AZN LLY NVO SNY

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

May 18, 2026, 8:00 AM EDT - 3 days ago

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

May 14, 2026, 2:22 PM EDT - 7 days ago

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

DGX MO CL

Pfizer price target raised to $26 from $25 at Wolfe Research

2026-05-14T17:29:38.000Z - 7 days ago

Pfizer price target raised to $26 from $25 at Wolfe Research

Mixed options sentiment in Pfizer with shares up 0.48%

2026-05-13T19:23:39.000Z - 8 days ago

Mixed options sentiment in Pfizer with shares up 0.48%

Arvinas price target raised to $16 from $14 at BofA

2026-05-13T19:22:15.000Z - 8 days ago

Arvinas price target raised to $16 from $14 at BofA

ARVN RIGL

Pfizer says EC grants marketing approval to expand indication for Hympavzi

2026-05-13T11:10:14.000Z - 8 days ago

Pfizer says EC grants marketing approval to expand indication for Hympavzi

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

May 13, 2026, 6:45 AM EDT - 8 days ago

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

Pfizer (PFE) Delivered a Solid Q1. The Patent Cliff Keeps Me Bearish

2026-05-13T07:12:25.000Z - 9 days ago

Pfizer (PFE) Delivered a Solid Q1. The Patent Cliff Keeps Me Bearish

LLY NVO

H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’

2026-05-12T17:45:03.000Z - 9 days ago

H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’

ARVN RIGL

Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu

2026-05-12T16:35:26.000Z - 9 days ago

Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu

ARVN RIGL

Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer

2026-05-12T13:02:04.000Z - 9 days ago

Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer

ARVN RIGL

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

May 12, 2026, 8:00 AM EDT - 9 days ago

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

ARVN RIGL

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

May 12, 2026, 7:00 AM EDT - 9 days ago

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

ARVN

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:09 PM EDT - 16 days ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 4:02 PM EDT - 16 days ago

Pfizer CEO on AI-designed molecule, and race to use new tech

3 Dividend Stocks for May 2026

May 5, 2026, 11:30 AM EDT - 16 days ago

3 Dividend Stocks for May 2026

SYY WSO

Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 16 days ago

Pfizer Earnings Call Transcript: Q1 2026

Pfizer Earnings release: Q1 2026

May 5, 2026, 10:00 AM EDT - 16 days ago

Pfizer Earnings release: Q1 2026

Pfizer Quarterly report: Q1 2026

May 5, 2026, 10:00 AM EDT - 16 days ago

Pfizer Quarterly report: Q1 2026

Pfizer Slides: Q1 2026

May 5, 2026, 10:00 AM EDT - 16 days ago

Pfizer Slides: Q1 2026

Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 8:35 AM EDT - 16 days ago

Pfizer Posts Better-Than-Expected Revenue, Profit

Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

May 5, 2026, 7:23 AM EDT - 16 days ago

Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates

May 5, 2026, 7:06 AM EDT - 16 days ago

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates

Why selling these 3 dividend stocks could be a mistake

May 5, 2026, 7:05 AM EDT - 16 days ago

Why selling these 3 dividend stocks could be a mistake

EPD UPS

Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

May 5, 2026, 6:55 AM EDT - 16 days ago

Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis

May 5, 2026, 6:51 AM EDT - 16 days ago

Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

May 5, 2026, 6:45 AM EDT - 16 days ago

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

US FDA approves Pfizer, Arvinas' breast cancer drug

May 1, 2026, 12:37 PM EDT - 20 days ago

US FDA approves Pfizer, Arvinas' breast cancer drug

ARVN

Pfizer's blood cancer drug meets main goal in late-stage trial

Apr 29, 2026, 7:42 AM EDT - 22 days ago

Pfizer's blood cancer drug meets main goal in late-stage trial

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

Apr 29, 2026, 6:45 AM EDT - 22 days ago

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

Pfizer secures deals to keep heart drug free of generic rivals until 2031

Apr 28, 2026, 10:41 AM EDT - 23 days ago

Pfizer secures deals to keep heart drug free of generic rivals until 2031

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Apr 28, 2026, 10:17 AM EDT - 23 days ago

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy

Apr 24, 2026, 8:36 AM EDT - 27 days ago

Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy

BMY

Pfizer Transcript: AGM 2026

Apr 23, 2026, 9:00 AM EDT - 4 weeks ago

Pfizer Transcript: AGM 2026

Pfizer Declares Second-Quarter 2026 Dividend

Apr 22, 2026, 4:45 PM EDT - 4 weeks ago

Pfizer Declares Second-Quarter 2026 Dividend

Pfizer GLP-1 weight loss drug available for pre-order in China

Apr 22, 2026, 5:18 AM EDT - 4 weeks ago

Pfizer GLP-1 weight loss drug available for pre-order in China

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

Apr 21, 2026, 11:51 AM EDT - 4 weeks ago

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says

Apr 20, 2026, 3:05 PM EDT - 4 weeks ago

Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Apr 20, 2026, 6:45 AM EDT - 4 weeks ago

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

The Big 3: PFE, V, SYF

Apr 16, 2026, 1:01 PM EDT - 5 weeks ago

The Big 3: PFE, V, SYF

SYF V

Big Pharma Is Turning to China for the Newest Drug Ideas

Apr 10, 2026, 11:00 PM EDT - 5 weeks ago

Big Pharma Is Turning to China for the Newest Drug Ideas

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Apr 9, 2026, 10:00 AM EDT - 6 weeks ago

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

Apr 2, 2026, 11:14 AM EDT - 7 weeks ago

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

NVO LLY

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Apr 1, 2026, 11:39 AM EDT - 7 weeks ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

BNTX

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Apr 1, 2026, 10:13 AM EDT - 7 weeks ago

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

Mar 30, 2026, 10:44 AM EDT - 7 weeks ago

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

GSK LLY NVO PPH

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

Mar 24, 2026, 10:00 AM EDT - 2 months ago

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

Mar 23, 2026, 12:46 PM EDT - 2 months ago

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

VALN

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Mar 23, 2026, 9:36 AM EDT - 2 months ago

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

VALN

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Mar 23, 2026, 7:07 AM EDT - 2 months ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

VALN

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

Mar 23, 2026, 7:02 AM EDT - 2 months ago

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

VALN

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Mar 23, 2026, 6:47 AM EDT - 2 months ago

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

VALN

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Mar 23, 2026, 6:45 AM EDT - 2 months ago

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

VALN

5 ‘Healthy' Dividends Paying Up To 14.1%

Mar 22, 2026, 9:45 AM EDT - 2 months ago

5 ‘Healthy' Dividends Paying Up To 14.1%

ARE BME DOC HQH

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Mar 20, 2026, 4:30 PM EDT - 2 months ago

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Mar 19, 2026, 6:45 AM EDT - 2 months ago

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Mar 17, 2026, 7:49 AM EDT - 2 months ago

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Mar 17, 2026, 6:45 AM EDT - 2 months ago

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer Proxy statement: Proxy Filing

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Pfizer Proxy statement: Proxy Filing

Pfizer Proxy statement: Proxy Filing

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Pfizer Proxy statement: Proxy Filing

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Mar 9, 2026, 7:27 AM EDT - 2 months ago

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

TornadoChasers
TornadoChasers May. 22 at 9:20 AM
$RVSN $INTC $PFE Medical runners
0 · Reply
framus_morrigan
framus_morrigan May. 22 at 8:19 AM
$PFE it could go very bearish this month but it didn't. So I'm reviewing the weekly chart. Bull channel while $25 keeps holding. Weekly chart
0 · Reply
Roctoc3880
Roctoc3880 May. 22 at 6:13 AM
$PFE buy
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 3:39 AM
$SLS - the 80th Event PR and ensuing Share Price Launch is Imminent. - Phase 3 Registrational Results and FDA Green light worth $40B to big Pharma - are Coming. ANY - DAY - NOW - GPS P3 Results - truly worth $40B + the Instant the REGAL Results are announced - GPS MOS 30-36 months, BAT 8-10 --- T1 Trading Halt - Gap Up into the $10B MCap Range / $50 Per Share - AND CLIMBING —- > And to Bottom LINE 009 - its worth $27 Per Share Right Now / TAMBICICLIB Will Be FDA Approved - the Market Has yet to appreciate its value. -- Gleevic - Imatinib, Imbrutinib -- Imbruvica, -- Upadactinib -- Rinvoq Upadactinib <- say that 3 x fast $PFE Pfizers' Ibrance - Palbociclib CDKinase Inhibitor Novartis' Kisqali -Ribociclib CDKinase Inhibitor $LLY Eli Lilly's Verzenio - Abemaciclib CDKinase Inhibitor $SLS Tambiciclib CDKInase Inhibitor reddit.com/r/sellasLifescience ... for anyone interested in DD/ i been here -invested a long time/ if you have an interest in $
0 · Reply
biolover
biolover May. 22 at 1:11 AM
$LLY $NVO $PFE $VKTX Novo dropped its dual agonist NN130 since then Due to Poor efficacy / telorability , and Bourla decided to run after GLp1 / amylin in phase 1 that will be a failure due to GI issues.
0 · Reply
morgangj
morgangj May. 22 at 1:09 AM
$PFE
0 · Reply
biolover
biolover May. 22 at 1:07 AM
$LLY $PFE $VKTX did Bourla look at numbers below prior to being stingy and running after Metsera ?
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 12:14 AM
$SLS it is inevitable - the 80th Event PR is coming, Phase 3 Registrational Results and FDA Green light worth $40B to big Pharma - are Coming. ANY - DAY - NOW, GPS P3 Results - truly worth $40B + the Instant the REGAL Results are announced - GPS MOS 30-36 months, BAT 8-10 --- T1 Trading Halt - Gap Up into the $10B MCap Range / $50 Per Share - AND CLIMBING And to Bottom LINE 009 - its worth $27 Per Share Right Now / TAMBICICLIB Will Be FDA Approved - the Market Has yet to appreciate its value. -- Gleevic - Imatinib, Imbrutinib -- Imbruvica, -- Upadactinib -- Rinvoq Upadactinib <- say that 3 x fast $PFE Pfizers' Ibrance - Palbociclib CDKinase Inhibitor Novartis' Kisqali -Ribociclib CDKinase Inhibitor $LLY Eli Lilly's Verzenio - Abemaciclib CDKinase Inhibitor $SLS Tambiciclib CDKInase Inhibitor reddit.com/r/sellasLifescience ... for anyone interested in DD/ i been here -invested a long time/ if you have an interest in $
1 · Reply
morgangj
morgangj May. 21 at 10:15 PM
$PFE
1 · Reply
Micheal_Pothead
Micheal_Pothead May. 21 at 7:49 PM
$PFE okay I’m getting worried now
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 May. 21 at 7:41 PM
$PFE - Impressive volumen’t
1 · Reply
Find_the_Cure
Find_the_Cure May. 21 at 7:34 PM
$PFE Trash Hauling needed here
0 · Reply
nimii
nimii May. 21 at 6:50 PM
$PFE give me 28
0 · Reply
pasuny
pasuny May. 21 at 6:05 PM
$PFE You guys are like, we are up 0.3%! OMG! This is the best day of my life! Pathetic.
1 · Reply
JBS_84
JBS_84 May. 21 at 5:11 PM
$PFE A few minutes ago there was a huge red volume bar. This is one of many examples of what I refer to as games. Look it up. They will hide large buys in these red volume bars to try and fool you. It was mostly a million dollar order at 25.8. But at a glance retail will see it as major selling pressure and in turn sell their shares probably directly to some institutional trader. Keep in mind the institutions make money off of retail fools. Don't be one of them. Look for these games. Think like they do
0 · Reply
BillionerOfKing
BillionerOfKing May. 21 at 4:55 PM
$PFE Current Stock Price: $25.81 Contracts to trade: $26.0 PFE May 22 2026 Call Entry: $0.07 Exit: $0.12 ROI: 71% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Mrdrifter
Mrdrifter May. 21 at 3:56 PM
$PFE MACD cross and perched on the averages. Looks like it wants 26.40s soon
1 · Reply
JBS_84
JBS_84 May. 21 at 3:42 PM
$PFE Don't fall for games here. Daily macd is about to cross over and it's riding crucial moving averages. Games will probably be played until next week to wash out as much retail as possible.
1 · Reply
pasuny
pasuny May. 21 at 3:25 PM
$PFE Jesus Pho King Christ... The CEO in human history!!! We gotta gotta do something about it!!! Fire the CEO!!!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 21 at 2:57 PM
$SLS $LLY $PFE these are the precise days to be loading..
0 · Reply
pasuny
pasuny May. 21 at 2:37 PM
$PFE Miserable company... So pathetic...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 21 at 2:36 PM
$SLS $LLY $PFE THE MOMENT THE 80th EVENT PR is announced, we ALL WILL WISH WE BOUGHT MORE SHARES RIGHT NOW . . . Fact.
0 · Reply